Balyasny Asset Management
RARE icon

Balyasny Asset Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Balyasny Asset Management’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.05M Sell
384,364
-135,690
-26% -$3.06M 0.01% 1135
2025
Q4 		$12M Buy
+520,054
New +$17.1M 0.02% 944
2025
Q3 		– Sell
-70,495
Closed -$2.11M – 3376
2025
Q2 		$2.56M Sell
70,495
-42,270
-37% -$1.52M ﹤0.01% 1605
2025
Q1 		$4.08M Buy
112,765
+2,865
+3% +$119K 0.01% 1352
2024
Q4 		$4.62M Buy
+109,900
New +$5.45M 0.01% 1322
2024
Q2 		– Sell
-28,743
Closed -$1.34M – 3005
2024
Q1 		$1.34M Sell
28,743
-54,190
-65% -$2.56M ﹤0.01% 1673
2023
Q4 		$3.97M Buy
+82,933
New +$3.22M 0.01% 1202
2023
Q1 		– Sell
-1,219
Closed -$56.5K – 3064
2022
Q4 		$56.5K Buy
+1,219
New +$47.9K ﹤0.01% 2334
2021
Q4 		– Sell
-3,553
Closed -$320K – 2532
2021
Q3 		$320K Buy
+3,553
New +$321K ﹤0.01% 1575
2021
Q2 		– Sell
-4,612
Closed -$525K – 2285
2021
Q1 		$525K Sell
4,612
-4,646
-50% -$632K ﹤0.01% 1391
2020
Q4 		$1.28M Buy
+9,258
New +$1.1M 0.01% 973
2019
Q4 		– Sell
-7,823
Closed -$335K – 1436
2019
Q3 		$335K Buy
+7,823
New +$425K ﹤0.01% 1004
2019
Q2 		– Sell
-12,034
Closed -$835K – 1688
2019
Q1 		$835K Sell
12,034
-2,614
-18% -$149K 0.01% 1070
2018
Q4 		$637K Buy
+14,648
New +$801K ﹤0.01% 1035
2018
Q1 		– Sell
-9,400
Closed -$436K – 2251
2017
Q4 		$436K Buy
+9,400
New +$461K ﹤0.01% 1598
2017
Q3 		– Sell
-7,700
Closed -$478K – 2059
2017
Q2 		$478K Buy
7,700
+2,600
+51% +$157K ﹤0.01% 1238
2017
Q1 		$346K Buy
5,100
+1,800
+55% +$137K ﹤0.01% 1371
2016
Q4 		$232K Buy
+3,300
New +$234K ﹤0.01% 1257
2016
Q1 		– Sell
-43,750
Closed -$4.91M – 1480
2015
Q4 		$4.91M Buy
43,750
+1,534
+4% +$153K 0.03% 502
2015
Q3 		$4.07M Buy
42,216
+12,216
+41% +$1.4M 0.03% 557
2015
Q2 		$3.07M Buy
+30,000
New +$2.33M 0.02% 687

Other funds holding RARE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Balyasny Asset Management's RARE Position: Q1 2026 in Review

Balyasny Asset Management reduced its Ultragenyx Pharmaceutical (RARE) stake by 26% in Q1 2026, selling an estimated $3.06M and leaving 384,364 shares worth $8.05M. The position accounts for 0.01% of the portfolio, ranked #1135.

Balyasny Asset Management first reported a position in RARE in Q2 2015 and has held it in 21 quarters since. The position peaked at $12M in Q4 2025. 295 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

  • Balyasny Asset Management held 384,364 shares of Ultragenyx Pharmaceutical worth $8.05M as of Q1 2026.
  • Balyasny Asset Management sold 135,690 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $3.06M.
  • Ultragenyx Pharmaceutical made up 0.01% of Balyasny Asset Management's portfolio in Q1 2026, its #1135 holding.
  • Balyasny Asset Management first reported a position in Ultragenyx Pharmaceutical in Q2 2015 and has held it in 21 quarters since.
  • Balyasny Asset Management's Ultragenyx Pharmaceutical position peaked at $12M in Q4 2025.
  • 295 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.